The Risk of Adrenal Insufficiency After Treatment With Relatlimab in Combination With Nivolumab is Higher Than Expected
This study is the first cohort analysis of hypophysitis in patients treated with relatlimab-nivolumab compared to nivolumab monotherapy. Combination treatment with relatlimab-nivolumab confers a significantly higher risk of developing adrenal insufficiency, likely secondary to hypophysitis, compared to nivolumab alone.
Authors
- Alexander T. Faje (ORCID: https://orcid.org/0000-0002-4092-5409)
- Natalia Chamorro-Pareja (ORCID: https://orcid.org/0000-0003-1354-1730)
- Karen Klahr Miller (ORCID: https://orcid.org/0000-0001-9438-2449)
Institutions
- Harvard University (US)
- Massachusetts General Hospital (US)
Publication Details
- Journal
- The Journal of Clinical Endocrinology & Metabolism
- Published
- 2025-02-26
- DOI
- https://doi.org/10.1210/clinem/dgaf122
- Citations
- 3
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 3.14